Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer
复制标题
DOI：
10.1007/s00280-003-0585-0
复制
发表时间：
2003-05-01
影响因子：
3
通讯作者：
Tominaga, K
中科院分区：
文献类型：
--
作者：
Mori, K;Kondo, T;Tominaga, K
目的：汉方药物Hangeshashin-to（TJ-14）含有黄芩苷（一种β-葡萄糖醛酸酶抑制剂），可缓解伊立替康（CPT-11）诱导的腹泻。我们进行了一项随机对照试验，以调查TJ-14是否可以预防和控制CPT-11引起的腹泻。研究方法：在44例既往未经治疗的晚期非小细胞肺癌患者中，41例（TJ-14组18例，对照组23例）可用于评估。化疗方案包括顺铂和CPT-11的组合。口服给予TJ-14（7.5g/天）。结果：41例患者中，39例发生腹泻。与对照组相比，TJ-14组显示出腹泻等级的显著改善（P = 0.044）以及3级和4级腹泻的频率降低（1名患者对10名患者; P = 0.018）。然而，两组在腹泻的频率或症状持续的天数方面没有差异。本研究在中期评估时停止。结论：TJ-14对CPT-11所致腹泻有较好的防治作用。
Purpose: Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a beta-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea. Methods: Of 44 previously untreated patients with advanced non-small-cell lung cancer randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation. The chemotherapy regimen consisted of a combination of cisplatin and CPT-11. TJ-14 (7.5 g/day) was administered orally. Results: Of the 41 patients, 39 experienced diarrhea. Compared with the control group, the TJ-14 group showed a significant improvement in diarrhea grades (P = 0.044) as well as a reduced frequency of diarrhea grades 3 and 4 (one patient versus ten patients; P = 0.018). However, the two groups showed no differences in the frequency of diarrhea or the number of days the symptoms continued. This study was stopped at an interim evaluation. Conclusion: TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea.